BR112018001907A2 - uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica - Google Patents

uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica

Info

Publication number
BR112018001907A2
BR112018001907A2 BR112018001907A BR112018001907A BR112018001907A2 BR 112018001907 A2 BR112018001907 A2 BR 112018001907A2 BR 112018001907 A BR112018001907 A BR 112018001907A BR 112018001907 A BR112018001907 A BR 112018001907A BR 112018001907 A2 BR112018001907 A2 BR 112018001907A2
Authority
BR
Brazil
Prior art keywords
treatment
lupus nephritis
antibodies
therapeutic
prevention
Prior art date
Application number
BR112018001907A
Other languages
English (en)
Inventor
Henry Nabozny Gerald
Steffgen Juergen
Ramanujam Meera
Scholl Paul
Ronald BRODEUR Scott
b freeman Thomas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BR112018001907A2 publication Critical patent/BR112018001907A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a anticorpos antagonistas anti-cd40 humanizados e métodos de terapêutica e diagnóstico e composições para uso dos mesmos no tratamento e/ou prevenção de nefrite lúpica.
BR112018001907A 2015-09-01 2016-08-31 uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica BR112018001907A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US201662287587P 2016-01-27 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Publications (1)

Publication Number Publication Date
BR112018001907A2 true BR112018001907A2 (pt) 2018-09-25

Family

ID=56896810

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001907A BR112018001907A2 (pt) 2015-09-01 2016-08-31 uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica

Country Status (16)

Country Link
US (3) US20170058038A1 (pt)
EP (1) EP3344655B1 (pt)
JP (2) JP2018529661A (pt)
KR (1) KR20180039172A (pt)
CN (1) CN107922501A (pt)
AU (1) AU2016317028B2 (pt)
BR (1) BR112018001907A2 (pt)
CA (1) CA2993996A1 (pt)
CL (1) CL2018000317A1 (pt)
DK (1) DK3344655T3 (pt)
ES (1) ES2969968T3 (pt)
HU (1) HUE063528T2 (pt)
MX (1) MX2018002447A (pt)
PH (1) PH12018500445A1 (pt)
PL (1) PL3344655T3 (pt)
WO (1) WO2017040566A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
CA3101469A1 (en) * 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
KR20210097750A (ko) * 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
JP2024506831A (ja) 2021-01-28 2024-02-15 リジェネロン・ファーマシューティカルズ・インコーポレイテッド サイトカイン放出症候群を治療するための組成物及び方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
MX9305070A (es) 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2006073443A2 (en) * 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
ES2354865T3 (es) * 2005-05-26 2011-03-18 Seattle Genetics, Inc. Anticuerpos anti-cd40 humanizados y métodos para utilizarlos.
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
RS57114B1 (sr) * 2010-03-31 2018-06-29 Boehringer Ingelheim Int Anti-cd40 antitela
SG194701A1 (en) * 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Also Published As

Publication number Publication date
JP2021185169A (ja) 2021-12-09
PH12018500445A1 (en) 2018-09-10
WO2017040566A1 (en) 2017-03-09
JP2018529661A (ja) 2018-10-11
AU2016317028A1 (en) 2018-02-22
AU2016317028B2 (en) 2021-09-09
EP3344655B1 (en) 2023-07-26
CL2018000317A1 (es) 2018-07-20
MX2018002447A (es) 2018-06-15
CA2993996A1 (en) 2017-03-09
KR20180039172A (ko) 2018-04-17
EP3344655A1 (en) 2018-07-11
US20190177420A1 (en) 2019-06-13
DK3344655T3 (da) 2023-10-09
PL3344655T3 (pl) 2024-02-19
ES2969968T3 (es) 2024-05-23
US20230265203A1 (en) 2023-08-24
HUE063528T2 (hu) 2024-01-28
US20170058038A1 (en) 2017-03-02
CN107922501A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
BR112017017927A2 (pt) receptores quiméricos de antígenos anti-dll3 e métodos de uso
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
PH12016502167A1 (en) Hdl theraphy markers
BR112017009297A2 (pt) anticorpos antifator de complemento c1q humanizados e usos dos mesmos
BR112016014731A2 (pt) Anticorpos anti-baff
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
EA201690159A1 (ru) Способы и композиции для лечения рака
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
ECSP16008797A (es) Derivados de heterobicicloaril como inhibidores rorc2 y métodos de uso de los mismos
BR112016019176A2 (pt) anticorpos il-21
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
BR112017009000A2 (pt) apilimod para uso no tratamento de melanoma
BR112018001907A2 (pt) uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
CL2020003348A1 (es) Anticuerpos anti–cd40 para su uso en el tratamiento de enfermedades autoinmunes
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EA201691896A1 (ru) Соединения и способы их применения
BR112017016396A2 (pt) composto, composição farmacêutica, uso de um composto, e, método.
EA201691452A1 (ru) Композиции для применения в лечении аллергических состояний
PH12019502694A1 (en) Anti-trkb antibodies
EA201790020A1 (ru) Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]